Russia: Viagra maker sues over cheaper rival
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Russian men looking to improve sexual performance on the cheap will lose their cut-price medicinal assistance if the pharmaceutical giant Pfizer is successful in a lawsuit against a generic competitor to its drug Viagra.
Pfizer says that Teva, a pharmaceutical company, is violating a patent, valid until 2014, that Pfizer holds to sell sildenafil-based medicines for treating erectile dysfunction.
A spokesman for Pfizer said Teva was already importing and selling its treatments on the Russian market, and the company said it would "take all necessary measures" to protect its brand.
Sildenafil, the active ingredient in Viagra, was initially developed to treat heart-related conditions, but during clinical trials it turned out that men experienced spontaneous erections. It was launched as Viagra in 1998 and re-patented in 2002 as a treatment for erectile dysfunction.
In the United States, Pfizer won a lawsuit against Teva last month, which bans the competitor from launching the drug until 2019. The US is by far the biggest market for the drug, and accounts for around half of all sales.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments